Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.

PloS one - 1 Jan 2018

Joshi Sandeep S, Jiang Shunlin, Unni Emmanual, Goding Stephen R, Fan Tao, Antony Paul A, Hornyak Thomas J

Abstract excerpt

Heat shock protein 90 (HSP90) is a molecular chaperone which stabilizes client proteins with important roles in tumor growth. 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90 ATPase activity, occupies the ATP binding site of HSP90 causing a conformational change which destabilizes client proteins and directs them towards proteosomal degradation. Malignant melanomas have active RAF-MEK-ERK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Immunotherapy, Adoptive

Share to Lactams, Macrocyclic

Share to Melanoma, Experimental

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 29481571
DOI: 10.1371/journal.pone.0191264
PMCID: PMC5826531

Genes

BRAF
NRAS
DCT
TYR
TYRP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.PMID 29481571Read ↗

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Semantic proximity Read ↗

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Semantic proximity Read ↗

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.Semantic proximity Read ↗

Catestatin suppresses melanoma progression and drug resistance through multitargeted modulation of signaling pathwaysSemantic proximity Read ↗

Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.Semantic proximity Read ↗

Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.Semantic proximity Read ↗

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.Semantic proximity Read ↗

Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathwaysSemantic proximity Read ↗

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.Semantic proximity Read ↗

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.Semantic proximity Read ↗

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.Semantic proximity Read ↗

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.